Randomized Controlled Trial

Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.

Jpn. J. Clin. Oncol. 2021 Mar 3; 51 (3): 345-353.
Article

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Clin. Breast Cancer. 2020 Apr 1; 20 (2): 174-181.e3.